|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Novo Nordisk A/S (NVO)'s Insulin Tresiba Has Heart Safety Risks, FDA Says
11/6/2012 8:20:23 AM
Novo Nordisk A/S (NOVOB)’s once-a-day insulin medicine Tresiba carries a higher heart risk than other diabetes treatments, U.S. regulators said. Novo’s shares dropped. Food and Drug Administration staff questioned whether more safety studies should be conducted on the product, also known as degludec, according to a report posted on the FDA website today ahead of a Nov. 8 meeting of agency advisers. Novo, the world’s largest insulin maker, designed the longer-lasting, higher-dose insulin to replicate the steady stream of the hormone that healthy people produce over 24 hours. Novo, based in Bagsvaerd, Denmark, is seeking to wrest market share from Paris-based Sanofi (SAN)’s best-selling Lantus insulin, which last year generated 3.92 billion euros ($5 billion) in revenue. Tresiba may produce about 9 billion kroner ($1.5 billion) in 2016 for Novo, according to the average of eight analysts’ estimates compiled by Bloomberg. Studies “consistently pointed to potential harm associated with the use of the insulin degludec products,” the FDA staff wrote in its report.
|
|
|
|
|
|
|
|
|
|
|